Premature ovarian failure (POF, also called primary ovarian insufficiency or early menopause) is a common gynecological endocrine disease characterized by the loss of ovarian function in women below 40 years. Most often, it is a non-reversible pathology leading to infertility. Normally, ovaries produce hormones and eggs until the early fifties, when they stop working and most women enter menopause. However, phenomena such as the dysfunction and the depletion of follicles (the cellular aggregates in the ovaries secreting hormones that influence the menstrual cycle) lead to POF, whose prevalence is 1/250 in women under 35 years and 1/100 in women under 40 years; the consequent loss of ovarian reserve (the number of follicles remaining in a womanﾒs ovaries) increases the risk of infertility, severely affecting women both physically and mentally. This report contains market size and forecasts of Premature Ovarian Failure Cure in Global, including the following market information: Global Premature Ovarian Failure Cure Market Revenue, 2017-2022, 2023-2028, ($ millions) Global top five companies in 2021 (%) The global Premature Ovarian Failure Cure market was valued at 900.2 million in 2021 and is projected to reach US$ 1473.4 million by 2028, at a CAGR of 7.3% during the forecast period 2022-2028. The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028. Hormone Replacement Therapy (HRT) Segment to Reach $ Million by 2028, with a % CAGR in next six years. The global key manufacturers of Premature Ovarian Failure Cure include Pfizer, Bayer, Novartis, Bioscience Institute, Johns Hopkins Medicine, Mayo Clinic, Baptist Health and Indira IVF, etc. In 2021, the global top five players have a share approximately % in terms of revenue. MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Premature Ovarian Failure Cure companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks. Total Market by Segment: Global Premature Ovarian Failure Cure Market, by Type, 2017-2022, 2023-2028 ($ millions) Global Premature Ovarian Failure Cure Market Segment Percentages, by Type, 2021 (%) Hormone Replacement Therapy (HRT) Calcium and Vitamin D Supplements In Vitro Fertilization (IVF) Stem Cell Therapy Others Global Premature Ovarian Failure Cure Market, by Application, 2017-2022, 2023-2028 ($ millions) Global Premature Ovarian Failure Cure Market Segment Percentages, by Application, 2021 (%) Less than 20 Years Old 20 to 30 Years Old 30 to 45 Years Old 45 Years Old and Older Global Premature Ovarian Failure Cure Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) Global Premature Ovarian Failure Cure Market Segment Percentages, By Region and Country, 2021 (%) North America US Canada Mexico Europe Germany France U.K. Italy Russia Nordic Countries Benelux Rest of Europe Asia China Japan South Korea Southeast Asia India Rest of Asia South America Brazil Argentina Rest of South America Middle East & Africa Turkey Israel Saudi Arabia UAE Rest of Middle East & Africa Competitor Analysis The report also provides analysis of leading market participants including: Key companies Premature Ovarian Failure Cure revenues in global market, 2017-2022 (estimated), ($ millions) Key companies Premature Ovarian Failure Cure revenues share in global market, 2021 (%) Further, the report presents profiles of competitors in the market, key players include: Pfizer Bayer Novartis Bioscience Institute Johns Hopkins Medicine Mayo Clinic Baptist Health Indira IVF
1 Introduction to Research & Analysis Reports 1.1 Premature Ovarian Failure Cure Market Definition 1.2 Market Segments 1.2.1 Market by Type 1.2.2 Market by Application 1.3 Global Premature Ovarian Failure Cure Market Overview 1.4 Features & Benefits of This Report 1.5 Methodology & Sources of Information 1.5.1 Research Methodology 1.5.2 Research
